THE DIAGNOSTIC EFFICACY OF URINARY VASCULAR ENDOTHELIAL GROWTH FACTOR IN EARLY STAGE 2 DIABETIC NEPHROPATHY
Journal: Matrix Science Pharma (MSP)
Author: Pang LL
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
ABSTRACT
Objectives: The objective was to analyze the application of vascular endothelial growth factor (VEGF) in the diagnosis of early type 2 diabetic nephropathy (DN). Methods: Thirty‑eight patients with type 2 DN diagnosed and treated from March 2016 to August 2017 were selected as the study group and another 38 healthy controls were selected as the control group. The two groups were examined by enzyme‑linked immunosorbent assay. Two groups of VEGF, serum creatinine, and glycosylated hemoglobin were observed and recorded. Results: Compared with the control group, the VEGF was higher in the observation group, and there was statistically significant difference between the two groups (P < 0.05). Compared with the control group, the specificity of serum creatinine and glycosylated hemoglobin was more significant in the observation group, and there was statistically significant difference between the two groups (P < 0.05). Conclusions: The application of urinary VEGF in the early diagnosis of type 2 DN has some clinical diagnostic value.
| Pages | 19-22 |
| Year | 2019 |
| Issue | 1 |
| Volume | 3 |
